Next Article in Journal
RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X
Next Article in Special Issue
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Previous Article in Journal
Disruption of Beta-Cell Mitochondrial Networks by the Orphan Nuclear Receptor Nor1/Nr4a3
Previous Article in Special Issue
Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer

Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview

Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, 91–95 Splaiul Independenței, 050095 Bucharest, Romania
Center for Advanced Laser Technologies (CETAL), National Institute for Laser, Plasma and Radiation Physics, 409 Atomiștilor St., 77125 Măgurele, Romania
Department of General Surgery, Sf. Maria Clinical Hospital, ‘Carol Davila’ University of Medicine and Pharmacy, 37–39 Ion Mihalache Blvd., 011172 Bucharest, Romania
Department of Life and Environmental Sciences, ‘Horia Hulubei’ National Institute of Physics and Nuclear Engineering, 30 Reactorului, 077125 Măgurele, Romania
Life, Environmental and Earth Sciences Division, Research Institute of the University of Bucharest (ICUB), University of Bucharest, 91–95 Splaiul Independenţei, 050095 Bucharest, Romania
Department of Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd., 050474 Bucharest, Romania
Fetal Medicine Excellence Research Center, ‘Alessandrescu-Rusescu’ National Institute of Mother and Child Health, 120 Lacul Tei Blvd., 020395 Bucharest, Romania
Department of Surgical Oncology, Alexandru Trestioreanu Oncology Institute, ‘Carol Davila’ University of Medicine and Pharmacy, 252 Fundeni Rd., 022328 Bucharest, Romania
Author to whom correspondence should be addressed.
Authors have contributed equally.
Cells 2020, 9(1), 169;
Received: 24 November 2019 / Revised: 28 December 2019 / Accepted: 6 January 2020 / Published: 9 January 2020
(This article belongs to the Special Issue microRNA as Biomarker)
Ovarian cancer has the highest mortality rate among gynecological cancers. Early clinical signs are missing and there is an urgent need to establish early diagnosis biomarkers. MicroRNAs are promising biomarkers in this respect. In this paper, we review the most recent advances regarding the alterations of microRNAs in ovarian cancer. We have briefly described the contribution of miRNAs in the mechanisms of ovarian cancer invasion, metastasis, and chemotherapy sensitivity. We have also summarized the alterations underwent by microRNAs in solid ovarian tumors, in animal models for ovarian cancer, and in various ovarian cancer cell lines as compared to previous reviews that were only focused the circulating microRNAs as biomarkers. In this context, we consider that the biomarker screening should not be limited to circulating microRNAs per se, but rather to the simultaneous detection of the same microRNA alteration in solid tumors, in order to understand the differences between the detection of nucleic acids in early vs. late stages of cancer. Moreover, in vitro and in vivo models should also validate these microRNAs, which could be very helpful as preclinical testing platforms for pharmacological and/or molecular genetic approaches targeting microRNAs. The enormous quantity of data produced by preclinical and clinical studies regarding the role of microRNAs that act synergistically in tumorigenesis mechanisms that are associated with ovarian cancer subtypes, should be gathered, integrated, and compared by adequate methods, including molecular clustering. In this respect, molecular clustering analysis should contribute to the discovery of best biomarkers-based microRNAs assays that will enable rapid, efficient, and cost-effective detection of ovarian cancer in early stages. In conclusion, identifying the appropriate microRNAs as clinical biomarkers in ovarian cancer might improve the life quality of patients. View Full-Text
Keywords: ovarian cancer; microRNA; biomarker; early diagnosis; molecular clustering analysis ovarian cancer; microRNA; biomarker; early diagnosis; molecular clustering analysis
Show Figures

Figure 1

MDPI and ACS Style

Staicu, C.E.; Predescu, D.-V.; Rusu, C.M.; Radu, B.M.; Cretoiu, D.; Suciu, N.; Crețoiu, S.M.; Voinea, S.-C. Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview. Cells 2020, 9, 169.

AMA Style

Staicu CE, Predescu D-V, Rusu CM, Radu BM, Cretoiu D, Suciu N, Crețoiu SM, Voinea S-C. Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview. Cells. 2020; 9(1):169.

Chicago/Turabian Style

Staicu, Cristina Elena, Dragoș-Valentin Predescu, Călin Mircea Rusu, Beatrice Mihaela Radu, Dragos Cretoiu, Nicolae Suciu, Sanda Maria Crețoiu, and Silviu-Cristian Voinea. 2020. "Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview" Cells 9, no. 1: 169.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop